Bicara Therapeutics Inc. filings document the regulatory record of a clinical-stage biopharmaceutical issuer developing bifunctional therapies for solid tumors. Forms 8-K record financial results, business highlights, ficerafusp alfa clinical updates, material definitive agreements and other events, including common stock and pre-funded warrant financing.
The company’s proxy materials cover annual meeting proposals, board-class elections, auditor ratification and governance matters for an emerging growth company. The filings also describe capital-structure actions and formal exhibits tied to press releases, underwriting agreements and shareholder voting matters.
Bicara Therapeutics (BCAX) filed its Form 10-K describing a clinical-stage oncology business focused on its lead bifunctional candidate ficerafusp alfa, an EGFR-directed antibody fused to a TGF-β ligand trap. The company is conducting a global, double-blind Phase 2/3 FORTIFI-HN01 trial in 1L recurrent/metastatic HPV-negative HNSCC with a planned ~650-patient enrollment intended to enable an interim ORR-based analysis in mid-2027. Bicara reports Phase 1/1b data across multiple dose regimens: 1500mg QW, 750mg QW and 2000mg Q2W in combination with pembrolizumab, with efficacy signals including confirmed ORRs in the mid-50% range in selected cohorts, median duration of response of 21.7 months and a generally manageable safety profile. Financial and corporate disclosures include an aggregate non-affiliate market value of $376.7 million as of June 30, 2025, and 65,467,187 shares outstanding as of March 24, 2026.
Bicara Therapeutics Inc. will hold its 2026 annual stockholder meeting virtually on June 9, 2026, with a record date of April 15, 2026. Stockholders will vote on electing two Class II directors to terms ending in 2029 and ratifying KPMG LLP as independent auditor for 2026.
The board will shrink from ten to nine members, with director Nils Lonberg, Ph.D., not standing for re-election. Bicara describes its board committee structure, director independence, and nomination process, and outlines cash retainers and option grants for non-employee directors and 2025 compensation for key executives.
Bicara Therapeutics Chief Financial Officer Hyep Ivan exercised stock options and sold the resulting shares in a coordinated transaction. On April 21, 2026, he exercised options to acquire 9,200 shares of common stock at $3.7898 per share, then sold 9,200 shares in open-market trades at a weighted-average price of $23.0015 per share. These trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 13, 2025. After the transactions, he directly owned 145,355 common shares and had 39,744 stock options remaining, with the option award scheduled to vest in sixteen equal quarterly installments following April 5, 2023 and expiring on April 5, 2033.
BCAX reported Form 144 notices for proposed sales of Common Stock linked to option exercises and recent disposals by an individual shareholder. The filings show 9,200 shares tied to an exercise of stock options dated 04/21/2026 and earlier sales of 1,882, 13,555, 2,963, and 9,200 shares on 01/22/2026, 03/03/2026, 03/04/2026, and 03/23/2026, respectively, with dollar amounts shown for each disposition.
Bicara Therapeutics Inc. Chief Executive Officer Claire Mazumdar reported option exercises and a modest share sale. She exercised options to acquire a total of 37,760 shares of common stock at exercise prices of $3.7898, $4.4369, and $5.4537 per share, converting derivative awards into stock.
On the same date, she sold 15,000 shares of common stock in an open-market transaction at a weighted average price of $23.6097 per share, executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2025. After these transactions, she directly owns 362,152 shares of Bicara common stock.
BCAX notice of a proposed sale of 15,000 shares of Common Stock to be sold on 04/20/2026 following an exercise of stock options. The sale is listed as by UBS Financial Services, Inc. and shown as an issuer-related cash transaction.
The filing also lists prior open-market sales by Claire Mazumdar in March 2026, including transactions on 03/09/2026 for 36,766 shares ($704,657.16) and other March dates with smaller lots.
Bicara Therapeutics President and COO Ryan Cohlhepp reported an option exercise and related stock sales in Bicara Therapeutics Inc. common stock. He exercised stock options for 8,000 shares at an exercise price of $3.7898 per share, acquiring the same number of common shares.
On the same date, he sold a total of 12,500 common shares at a weighted average price of $23.0073 per share, executed in multiple transactions under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, he directly owns 196,141 common shares of Bicara Therapeutics Inc.
BCAX (Rule 144 filing) — Notice of proposed sales of Common Stock by a reporting person and record of recent open-market dispositions. The filing lists proposed option exercises of 4,500 and 8,000 shares and five completed sales on 01/15/2026, 01/22/2026, 02/25/2026, 03/03/2026, and 03/16/2026 with per-line proceeds shown.
BICARA THERAPEUTICS INC ownership update: T. Rowe Price Investment Management, Inc. reports beneficial ownership of 6,605,780 shares of common stock, representing 10.1% of the class as disclosed in an amended Schedule 13G/A. The filing states T. Rowe Price "hereby declares and affirms that the filing of shall not be construed as an admission that Price Investment Management is the beneficial owner," denying beneficial ownership. The report lists 6,597,481 shares as sole voting power and 6,605,780 shares as sole dispositive power. The filing is signed by Ellen York, Vice President, dated 04/08/2026.
Bicara Therapeutics Inc. provides its annual business update focused on ficerafusp alfa, a bifunctional EGFR/TGF-β antibody for solid tumors. The company is running the global double-blind FORTIFI-HN01 Phase 2/3 pivotal trial in first-line HPV-negative head and neck squamous cell carcinoma, targeting substantial enrollment by the end of 2026 and an interim analysis in mid-2027.
Earlier Phase 1/1b data in 1L recurrent/metastatic HPV-negative head and neck cancer showed a confirmed overall response rate of 54% at the 1500mg weekly dose in combination with pembrolizumab, with a median overall survival of 21.3 months. Bicara is also exploring ficerafusp alfa in additional tumors, including colorectal, cutaneous squamous cell, and anal squamous cell carcinomas, and reports a generally manageable safety profile dominated by EGFR-related rash and low-grade mucosal bleeding events.